Travere Therapeutics (TVTX) Tops Q1 EPS by 115c

Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.09), $1.15 better than the analyst estimate of ($1.24). Revenue for the quarter came in at $44 million versus the consensus estimate of $50.6 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity